The obesity paradox in non–ST-segment elevation acute coronary syndromes: Results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association Guidelines Quality Improvement Initiative - 18/08/11
, Matthew T. Roe, MD, MHS b, Jyotsna Mulgund, MS b, Charles V. Pollack, MD, MA c, J. Douglas Kirk, MD a, W. Brian Gibler, MD d, E. Magnus Ohman, MD e, Sidney C. Smith, MD e, William E. Boden, MD f, Eric D. Peterson, MD, MPH bRésumé |
Background |
Although obesity is a known risk factor for coronary artery disease, its impact on the presentation, treatment, and outcome of patients with acute coronary syndromes (ACS) has not been well studied.
Methods |
Using data from the CRUSADE Initiative, we compared inhospital treatments and clinical outcomes of 80845 patients with high-risk non–ST-segment elevation (NSTE) ACS (positive cardiac markers and/or ischemic ST-segment changes) to determine whether there was an association with body mass index (BMI [kg/m2]). Patient weights were categorized according to World Health Organization classifications: Underweight (BMI <18.5), Normal range (BMI 18.5-24.9), Overweight (BMI 25-29.9), Obese Class I (BMI 30-34.9), Obese Class II (BMI 35-39.9), and Extremely Obese (BMI =40).
Results |
Most (70.5%) of the CRUSADE patients were classified as overweight or obese; these patients were younger and more likely to present with comorbid conditions, including diabetes mellitus, hypertension, and hyperlipidemia. Medications given during the first 24 hours and invasive cardiac procedures recommended by the American College of Cardiology/American Heart Association guidelines for NSTE ACS were more commonly used in these patients. The incidence of death and death and reinfarction, adjusted for covariates, were generally lower in overweight and obese patients, compared with normal-weight patients, but higher in underweight and extremely obese patients.
Conclusions |
Most patients with NSTE ACS are overweight or obese. These patients receive more aggressive treatment, and, except for the extremely obese, have less adverse outcomes compared with underweight and normal-weight patients. Although obesity appears to be a risk factor for developing ACS at a younger age, it also appears to be associated with more aggressive ACS management and, ultimately, improved outcomes.
Le texte complet de cet article est disponible en PDF.Plan
| CRUSADE is funded by Millennium Pharmaceuticals, Inc, and Schering Corporation. Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership provides an unrestricted grant in support of the program. |
Vol 152 - N° 1
P. 140-148 - juillet 2006 Retour au numéro
Article précédent
- Estradiol increases platelet aggregation in PlA1/A1 individuals
- Konstantinos D. Boudoulas, Christine Roos Montague, Pascal J. Goldschmidt-Clermont, Glen E. Cooke
- Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: An analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial
- Vivek Rajagopal, A. Michael Lincoff, David J. Cohen, Hitinder S. Gurm, Tingfei Hu, Walter J. Desmet, Neal S. Kleiman, John A. Bittl, Frederick Feit, Eric J. Topol
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?